off-label

Judge Approves $600 Million Botox Settlement

A federal investigation into Allergan's misleading marketing of its wrinkle-smoothing Botox medication is over after a judge in Georgia on Tuesday approved the pharmaceutical firm's decision to pay $600 million and plead guilty to misbranding the product.

False Advertising vs. the First Amendment

You know better than to believe everything companies say in ads, but when it comes to claims about the healthfulness of foods and other products, the untruths can reach outrageous levels. The question is: What can a government limited by the First Amendment do to stop them?

Allergan Pays $600 Million to Settle Botox Charges

Pharmaceutical firm Allergan has settled criminal and civil charges that it promoted Botox for uses the FDA hadn't approved, agreeing to pay $600 million and enter into a "corporate integrity agreement." Allergan also dropped its related First Amendment lawsuit against the FDA.